Understanding polycythaemia vera diagnosis and care
Part of Blood & lymphatic, Cancer clinical trials.
This study asks doctors how they diagnose and treat polycythaemia vera (PV), a blood condition where the body makes too many red blood cells. Your answers will help improve care for future patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a board-certified hematology specialist (a doctor who treats blood disorders).
- You practice in a hospital or clinic in Saudi Arabia, Ukraine, or Türkiye.
- You have at least 3 years of experience managing patients with blood cancers or related conditions.
- You have cared for at least 10 PV patients in the past 3–5 years, or at least 3–5 PV patients in the past 12 months.
- You are able to give informed consent and complete the survey in English, Turkish, or Ukrainian.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial aims to improve how doctors document and assess care for patients with polycythemia vera (PV), a rare blood disorder. It may lead to more consistent and better-informed treatment decisions for people living with PV.
This study is testing a medicine called ropeginterferon alfa-2b for people with polycythemia vera (a blood condition) who do not have a swollen spleen that causes symptoms. It looks at how well the medicine works and how it affects your daily life through simple questionnaires.
This trial tests a new drug called 9MW3011 for people with polycythemia vera (PV) who haven't done well on or can't take standard treatments like hydroxyurea or interferon. The goal is to see if the drug is safe and how it works in your body.
This study watches how a blood condition called essential thrombocythemia (ET) changes into another condition called polycythemia vera (PV) in people with a specific JAK2 mutation. It aims to learn more about these changes and what happens to patients over time.
This study tests a new medicine called rusfertide for polycythemia vera (PV)—a blood condition where your body makes too many red blood cells. The trial aims to see if rusfertide can help reduce the need for blood removal procedures (phlebotomy) that PV patients currently need to manage their condition.
This study tests a new medicine called AG-236 in people with polycythemia vera (PV), a condition where the body makes too many red blood cells. The trial aims to see if AG-236 can reduce the need for phlebotomies (removing blood to lower red blood cell count) and help control the disease.
Hear when a new Polycythemia Vera trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.